NOVARX治疗性疫苗LUCANIX三期结果：中位生存期20个月，有放疗的达40个月。

javacoder

主要就是犹豫在安慰剂组上了

请带我去阿尔科

活在当下，现在你弟弟在哪治疗，用哪些药，我们一起努力用各种方法积极治疗，我刚复查完毕，原发有缩小，马上继续第三次培美曲赛+顺铂化疗，只是上次自己对顺铂反应比较大，第三天和第五天都吐，肠胃非常难受，不知道这次还能不能耐受，目前吃了半个月中药，感觉人的状态比上次好，但愿反应不大，不会造成化疗期间人状态低下有耐药或突变的癌细胞乘机爆发

nogamze33

有希望就好!

javacoder

有人有进一步的消息或者在联系入组吗？给大家说说吧 对这个比较关注

524001498

又一个希望

啊呀AYA

请问有 最新的消息吗？ 谢谢

扶摇

美国是么法去了，，中国啥时候开始啊

活在当下

NovaRx Announces Results of Lucanix® Phase III Therapeutic Vaccine Trial for Post-frontline Maintenance Therapy in Non-small Cell Lung Cancer to Be Presented at ESMO.

NovaRx Corporation announced that the detailed results from the randomized Phase III trial of Lucanix® (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer will be presented at the European Society for Medical Oncology 2013 annual meeting in Amsterdam. The results will be presented in "Presidential Session I: Best and Late Breaking Abstracts" on 28 September 2013, which starts at 1:45 pm.

The primary endpoint of improving overall survival in 532 patients was not met primarily due to the inclusion of patients more than 12 weeks following the completion of frontline chemotherapy.  In this predefined subgroup of 305 stage IIIB/IV patients, a median survival of 20.7 months was observed for Lucanix compared to 13.4 months for the control (HR 0.75).  In a the predefined subgroup of these patients with a histology of squamous cell carcinoma a media survival of 20.7 months was observed for Lucanix compared to 12.3 months for the control (HR 0.58).  In the predefined subgroup of these patients who received radiation therapy prior to enrollment a media survival of 40.1 months was observed for Lucanix compared to 10.3 months for the control (HR 0.45).

这次临床实验以提高532个病人的总生存期为主要目标，但并没能得以实现，原因是部分被纳入实验的病人是在前期化疗结束超过12个星期后，才加入实验组。在预先设置好的305个IIIB/IV期病人的小组中，Lucanix实验组的中位生存期是20.7个月，而控制组是13.4个月（HR 0.75）。对于鳞癌病人，Lucanix实验组的中位生存期是20.7，而控制组只有12.3个月 (HR 0.58)。而对于入组前，接受过放疗的病人，Lucanix的中位生存期是40.1个月，而控制组只有10.3个月（HR 0.45）。